RxDoctor Payments DataLook up a doctor →

Peter Kaiser, MD

Ophthalmology · Cleveland, OHNPI 1558300590

Payments from drug & device makers

$1,499,428in general payments, 2019–2025

Across 402 payments — averaging $3729.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$473K
  • Astellas Pharma US Inc$233K
  • AbbVie$180K
  • Novartis$159K
  • Novartis Pharma AG$76K
  • Regeneron$74K
  • plus $304K from 39 others
$79,797in research payments, 2019–2025

Across 22 payments — averaging $3627.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$42K
  • Novartis Pharma AG$34K
  • Regeneron$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,499,428 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$130,224
Medicare patients
567
Services billed
2,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →